Glucocorticoid use in acute lymphoblastic leukaemia
1Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-3678, USA. hiroto.inaba@stjude.org
The Lancet. Oncology
|October 16, 2010
Summary
Dexamethasone offers better event-free survival than prednisone in acute lymphoblastic leukaemia (ALL) treatment at specific doses, but it also increases adverse effects. Optimal glucocorticoid selection requires careful consideration of dose-dependent efficacy and toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Glucocorticoids like prednisone and dexamethasone are crucial for treating acute lymphoblastic leukaemia (ALL).
- Optimal dosing and bioequivalence of these glucocorticoids in ALL treatment remain undetermined.
- Preclinical data suggest dexamethasone has superior properties over prednisone, including longer half-life and enhanced central nervous system (CNS) penetration.
Purpose of the Study:
- To evaluate the comparative efficacy and safety of prednisone and dexamethasone in ALL treatment.
- To determine the optimal dose ratio and bioequivalence between prednisone and dexamethasone.
- To assess the impact of glucocorticoid type and dose on treatment outcomes and adverse events in ALL patients.
Main Methods:
- Prospective randomized trials were conducted to compare prednisone and dexamethasone efficacy.
- Analysis included event-free survival, CNS leukemia control, and adverse event profiles.
- In vitro studies assessed the cytotoxic effects of both drugs on ALL cells.
Main Results:
- Dexamethasone demonstrated improved event-free survival compared to prednisone at a prednisone-to-dexamethasone dose ratio below seven.
- High-dose dexamethasone (10-18 mg/m(2)/day) improved outcomes in T-cell ALL and high-risk ALL.
- Dexamethasone use was associated with a higher incidence of adverse effects, including infections and bone fractures.
- No significant efficacy difference was observed between the drugs at a dose ratio greater than seven.
- Individual patient variations influenced the dose ratios for equivalent cytotoxic effects in vitro.
Conclusions:
- The efficacy of prednisone and dexamethasone in ALL is dose-dependent and must be balanced against their toxic effects.
- Dexamethasone shows promise for improved outcomes in specific ALL subgroups, but careful monitoring for adverse events is necessary.
- Individualized selection of glucocorticoid type and dose is recommended, considering relapse risk, treatment phase, and concomitant chemotherapy.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...